
Group 1 - The infant formula market is experiencing a recovery in the first half of 2025, with several companies reporting positive earnings forecasts, indicating sustained growth [1][2] - Child King (301078.SZ) expects a net profit of 120 million to 160 million yuan, a year-on-year increase of 50% to 100%, driven by steady growth in self-operated business and the expansion of its franchise model in lower-tier markets [2] - Health and Happiness Group (01112.HK) reported single-digit revenue growth, with a strong performance in the ultra-premium infant formula segment, increasing its market share from 13% to 15.8% [2] Group 2 - According to Nielsen IQ data, the total sales of infant formula maintained growth for three out of five months leading up to May 25, 2025, with strong sales in the first and second stages of formula [3] - After four years of decline, the domestic birth rate increased to 9.54 million in 2024, contributing to the recovery of the infant formula market, although there are concerns about a potential slight decline in birth rates in 2025 [6] Group 3 - A subsidy war initiated in April 2025 has intensified competition in the infant formula market, with several companies, including China Feihe (06186.HK) and Yili (600887.SH), launching substantial subsidy programs [7][8] - The subsidy strategy primarily involves offering free formula, leading to consumer behavior where multiple brands' products are exchanged among consumers, complicating sales for companies [7][8] - China Feihe issued a profit warning, expecting revenue between 9.1 billion and 9.3 billion yuan for the first half of 2025, down from 10.1 billion yuan in the same period of 2024, attributing the decline to the subsidy program [8]